NAM
ALNY icon

NorthCrest Asset Manangement’s Alnylam Pharmaceuticals ALNY Stock Holding History

NorthCrest Asset Manangement’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,733
Closed -$689K – 774
2025
Q4 		$689K Buy
1,733
+128
+8% +$56.6K 0.02% 459
2025
Q3 		$738K Buy
+1,605
New +$654K 0.02% 393
2025
Q2 		– Sell
-1,196
Closed -$323K – 625
2025
Q1 		$323K Buy
+1,196
New +$307K 0.01% 504

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NorthCrest Asset Manangement's ALNY Position: Q1 2026 in Review

NorthCrest Asset Manangement sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,733 shares — an estimated $689K sold.

NorthCrest Asset Manangement first reported a position in ALNY in Q1 2025 and held it in 3 quarters. The position peaked at $738K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • NorthCrest Asset Manangement reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • NorthCrest Asset Manangement sold 1,733 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $689K.
  • NorthCrest Asset Manangement first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • NorthCrest Asset Manangement's Alnylam Pharmaceuticals position peaked at $738K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q1 2026, filed 8 Apr 2026.